Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

• Main Authors: Yuan Hong (Author), Xichuang Chen (Author), Yuanquan Hong (Author), Xingfang Xiao (Author), Yan Wang (Author), Xiaohong You (Author), Jingyi Mi (Author), Tao Zhou (Author), Panpan Zheng (Author), Zhihu Huang (Author)
• Format: Book
• Published: BMC, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (BE) plus rituximab (RI) for previous...